Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

Cancer cell therapy play Adaptimmune gained $2.66 (200%) to $3.99 on Monday after announcing a new set of data for its SPEAR T cell therapies in four different solid tumor indications.

The announcement by Adaptimmune Therapeutics plc (NASDAQ:ADAP) at the J.P. Morgan Healthcare Conference in San Francisco disclosed four partial responses across three Phase I trials, noting that responses came from a head and neck cancer patient and a metastatic rectal mucosal melanoma patient in the Phase I trial of ADP-A2M4; a hepatocellular carcinoma (HCC) patient treated with ADP-A2AFP; and a patient with metastatic gastro-esophageal junction cancer treated with the company’s next generation cell therapy ADP-A2M4CD8...